Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | BACE1 | P56817 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | NCEH1 | Q6PIU2 | 3/20 | 0.39 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4069517 | 0.81 | L3MBTL1 (0.40) | ALDH1A1HPGDCYP2C9CYP2C19POLB | |
| SCHEMBL17993036 | 0.80 | MAPT (0.40) | ALDH1A1HPGDPOLBL3MBTL1NCEH1 | |
| SCHEMBL4156146 | 0.80 | L3MBTL1 (0.49) | ALDH1A1HPGDHSD17B10CYP2C9CYP2C19 | |
| SCHEMBL29703387 | 0.80 | MAPT (0.40) | ALDH1A1HPGDPOLBL3MBTL1NCEH1 | |
| SCHEMBL2874915 | 0.80 | ALDH1A1 (0.46) | ALDH1A1HPGDPOLBL3MBTL1NCEH1 | |
| SCHEMBL8846907 | 0.80 | ALDH1A1 (0.40) | ALDH1A1HPGDPOLBL3MBTL1NCEH1 | |
| SCHEMBL2471899 | 0.78 | HSD17B10 (0.52) | ALDH1A1HSD17B10CYP2C9CYP2C19POLB | |
| SCHEMBL3493073 | 0.78 | PTGDR2 (0.54) | ALDH1A1HSD17B10CYP2C9CYP2C19POLB | |
| SCHEMBL2471344 | 0.77 | NR4A2 (0.43) | ALDH1A1HPGDHSD17B10CYP2C9CYP2C19 | |
| SCHEMBL4677215 | 0.76 | ALDH1A1 (0.62) | ALDH1A1HPGDHSD17B10POLBL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120252770-A1 | Chemical Compounds 572 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-10-04 | — | — | US | disclosed |
| US-20120252770-A1 | Chemical Compounds 572 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-10-04 | — | — | US | disclosed |
| US-20120252770-A1 | Chemical Compounds 572 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-10-04 | — | — | US | disclosed |
| CN-101611015-B | Indazolyl ester and indazolyl amide derivatives for the treatment of glucocorticoid receptor mediated disorders | ASTRAZENECA AB SE | 2012-09-26 | — | — | CN | disclosed |
| EP-2102169-B1 | INDAZOLYL AMIDE DERIVATIVES FOR THE TREATMENT OF GLUCOCORTICOID RECEPTOR MEDIATED DISORDERS | ASTRAZENECA AB (SE) | 2012-06-20 | — | — | EP | disclosed |
| US-8143290-B2 | Chemical compounds 572 | ASTRAZENECA AB (SE) | 2012-03-27 | — | — | US | disclosed |
| US-8143290-B2 | Chemical compounds 572 | ASTRAZENECA AB (SE) | 2012-03-27 | — | — | US | disclosed |
| US-8143290-B2 | Chemical compounds 572 | ASTRAZENECA AB (SE) | 2012-03-27 | — | — | US | disclosed |
| US-20110071194-A1 | Chemical Compounds 572 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-03-24 | — | — | US | disclosed |
| US-20110071194-A1 | Chemical Compounds 572 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-03-24 | — | — | US | disclosed |
| US-20100197644-A1 | Chemical Compounds 572 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2010-08-05 | — | — | US | disclosed |
| US-7728030-B2 | Chemical compounds 572 | ASTRAZENECA AB (SE) | 2010-06-01 | — | — | US | disclosed |
| US-7728030-B2 | Chemical compounds 572 | ASTRAZENECA AB (SE) | 2010-06-01 | — | — | US | disclosed |
| US-7728030-B2 | Chemical compounds 572 | ASTRAZENECA AB (SE) | 2010-06-01 | — | — | US | disclosed |
| CN-101611015-A | Indazolyl ester and indazolyl amide derivatives for the treatment of glucocorticoid receptor mediated disorders | ASTRAZENECA AB (SE) | 2009-12-23 | — | — | CN | disclosed |
| EP-2102169-A1 | INDAZOLYL ESTER AND AMIDE DERIVATIVES FOR THE TREATMENT OF GLUCOCORTICOID RECEPTOR MEDIATED DISORDERS | AstraZeneca AB (SE) | 2009-09-23 | — | — | EP | disclosed |
| US-20080214641-A1 | Chemical compounds 572 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2008-09-04 | — | — | US | disclosed |
| US-20080214641-A1 | Chemical compounds 572 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2008-09-04 | — | — | US | disclosed |
| US-20080214641-A1 | Chemical compounds 572 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2008-09-04 | — | — | US | disclosed |
| WO-2008076048-A1 | INDAZOLYL ESTER AND AMIDE DERIVATIVES FOR THE TREATMENT OF GLUCOCORTICOID RECEPTOR MEDIATED DISORDERS | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214641-A1 | Chemical compounds 572 | ABCG2, ABCB1, CYP11B2 | ALDH1A1 699/4885HPGD 254/4885HSD17B10 1784/4885 |
| US-20100197644-A1 | Chemical Compounds 572 | ABCG2, ABCB1, CYP11B2 | ALDH1A1 699/4885HPGD 254/4885HSD17B10 1784/4885 |
| US-20120252770-A1 | Chemical Compounds 572 | ABCG2, ABCB1, CYP11B2 | ALDH1A1 699/4885HPGD 254/4885HSD17B10 1784/4885 |
| US-20110071194-A1 | Chemical Compounds 572 | ABCG2, ABCB1, CYP11B2 | ALDH1A1 699/4885HPGD 254/4885HSD17B10 1784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.